Seikagaku Corporation

Meiji Milk Products Company, Limited

Japan Tissue Engineering Co., Ltd.

Cellmid Limited

Medical Therapies Limited

Takashi Muramatsu

Hisako Muramatsu

Kazuhiko Inoh

Haruko Ogawa

Takaaki Kobayashi

Shuhei Torii

Itsuo Yokoyama

Kenichiro Hata

Tohru Takada

Kazuhiro Toriyama

Yukio Sumi

Minoru Ueda

Kazuhiko Unoki

Hitoshi Arimura

Akiko Okubo

Norio Ohba

The present inventors discovered that oligonucleotides which suppress midkine expression and antibodies which suppress midkine activity can be used to prevent post-surgical intraperitoneal adhesions.

Preventive for adhesion following abdominal surgery

Anti-midkine antibody for preventing post-laparotomy adhesions

A full-length cDNA is obtained by analyzing the partial amino acid sequence of purified endo-&#x3b2;-galactosidase C, constructing primers based thereon, effecting PCR with the use of the genomic DNA ofas a template to thereby obtain a fragment of cDNA encoding endo-&#x3b2;-galactosidase, effecting cassette PCR by using the cDNA fragment thus obtained to thereby obtain the 5'-terminal and 3&#x2032;-terminal domains, and further effecting PCR with the use of primers constructed on the basis of the data acquired above.

DNA coding for endo-&#x3b2;-galactosidase

Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its inhibitors can be used for treating neutrophilic functional disorders or inflammatory diseases.

Agents comprising midkine or an inhibitor thereof as active ingredient

DNA encoding endo-&#x3b2;-galactosidase

The pharmaceutical formulation for inhibiting wound contraction of the present invention includes secretory leukocyte protease inhibitor as an active ingredient. The SLPI concentration in the pharmaceutical formulation is preferably 1&#x2013;5000 ng/ml, and more preferably 1&#x2013;100 ng/ml. The pharmaceutical formulation for inhibiting wound contraction of the present invention may be prepared as an external preparation including a base and the SLPI as an active ingredient. The pharmaceutical formulation for inhibiting wound contraction of the present invention may be prepared as an injection including the SLPI as an active ingredient. The external preparation may preferably include a preservative. The injection may preferably include a stabilizer (an antioxidant), a preservative and an analgesic agent.

Wound contraction inhibitor

A method for treating retinal diseases includes administering an effective amount of midkine to patients suffering from retinal diseases. The method of the invention is effective in ameliorating optical disorders of retinas and is quite safe.

Method for treating retinal diseases

Growing community of inventors

Aichi, Japan

Hisako Muramatsu